NLG802
Phase 1Small molecule
NLG802 is one of 26 small molecule programs targeting Brain Cancer. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Brain Cancer
#DrugCompanyPhaseTrials
1Jevtana
SanofiApproved
Actos
TakedaApproved
Opdivo
Bristol-Myers SquibbPhase 3
Trisenox
CCephalon
Approved
Tarceva
OOSI Pharmaceuticals
Approved
Aloxi
AAvyxa
Approved
Photofrin
PPinnacle Biologics Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Glucophage
EMD SeronoApproved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
Stereotactic Body Radiotherapy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NLG802. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- LLuke, Jason, MD